Equities Analysts Offer Predictions for SPRY FY2026 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($0.45) for the year. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

SPRY has been the topic of several other research reports. Scotiabank assumed coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Trading Up 0.4%

ARS Pharmaceuticals stock traded up $0.06 during mid-day trading on Tuesday, reaching $14.40. The company had a trading volume of 588,557 shares, compared to its average volume of 1,522,917. The business has a fifty day simple moving average of $14.06 and a 200 day simple moving average of $12.84. The company has a market cap of $1.41 billion, a P/E ratio of -28.24 and a beta of 0.84. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million.

Institutional Trading of ARS Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new position in ARS Pharmaceuticals in the first quarter worth approximately $37,000. GAMMA Investing LLC boosted its holdings in ARS Pharmaceuticals by 4,319.7% in the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock worth $420,000 after acquiring an additional 3,283 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of ARS Pharmaceuticals by 78,100.0% during the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after acquiring an additional 3,905 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $73,000. Institutional investors and hedge funds own 68.16% of the company's stock.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 50,000 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $705,000.00. Following the sale, the chief financial officer now owns 7,424 shares of the company's stock, valued at approximately $104,678.40. This represents a 87.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now owns 210,346 shares of the company's stock, valued at approximately $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 332,971 shares of company stock worth $4,621,888. Insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.